THE ROLES OF ANTIFIBROTIC THERAPIES IN POST-SARS-CoV-2 INFECTION

Nur Azizah Nadhirah Binti Azni; Yong Qi Leong; Chooi Ling Lim; Khuen Yen Ng; Soi Moi Chye; Anna Pick Kiong Ling; Yin Yin Ooi; Rhun Yian Koh

THE ROLES OF ANTIFIBROTIC THERAPIES IN POST-SARS-CoV-2 INFECTION

Nur Azizah Nadhirah Binti Azni, Yong Qi Leong, Chooi Ling Lim, Khuen Yen Ng, Soi Moi Chye, Anna Pick Kiong Ling, Yin Yin Ooi, Rhun Yian Koh

Malaysia Sch of Pharmacy

Research output: Contribution to journal › Review Article › Research › peer-review

Abstract

Coronavirus Disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), has affected over hundred million people worldwide. Other than acute symptoms after infection, the patients are also suffering with long-term health complications associated with COVID-19 called long COVID or post-COVID conditions by which pulmonary fibrosis (PF) was observed in one-third of the patients. Since post-COVID-19-associated PF (PCPF) shares similar symptoms with idiopathic pulmonary fibrosis (IPF), the ongoing studies focuses on the potential use of therapeutic approaches for IPF in PCPF patients. Hence, this study summarises the potential roles of these therapies to treat the PCPF include antifibrotic drugs, mesenchymal stem cell (MSC) therapy and inhaled curcumin nanoformulations by assessing their efficacies for the PCPF treatment.

Original language	English
Pages (from-to)	77-82
Number of pages	6
Journal	Malaysian Journal of Biochemistry & Molecular Biology
Volume	26
Issue number	1
Publication status	Published - Apr 2023

Keywords

Antifibrotic therapies
Coronavirus Disease 19 (COVID-19)
Pulmonary fibrosis
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS)

Access to Document

https://msbmb2010.wixsite.com/mjbmb/december-2023

Cite this

@article{054ca2c950f845529bc2bc200879480e,

title = "THE ROLES OF ANTIFIBROTIC THERAPIES IN POST-SARS-CoV-2 INFECTION",

abstract = "Coronavirus Disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), has affected over hundred million people worldwide. Other than acute symptoms after infection, the patients are also suffering with long-term health complications associated with COVID-19 called long COVID or post-COVID conditions by which pulmonary fibrosis (PF) was observed in one-third of the patients. Since post-COVID-19-associated PF (PCPF) shares similar symptoms with idiopathic pulmonary fibrosis (IPF), the ongoing studies focuses on the potential use of therapeutic approaches for IPF in PCPF patients. Hence, this study summarises the potential roles of these therapies to treat the PCPF include antifibrotic drugs, mesenchymal stem cell (MSC) therapy and inhaled curcumin nanoformulations by assessing their efficacies for the PCPF treatment.",

keywords = "Antifibrotic therapies, Coronavirus Disease 19 (COVID-19), Pulmonary fibrosis, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS)",

author = "Azni, \{Nur Azizah Nadhirah Binti\} and Leong, \{Yong Qi\} and Lim, \{Chooi Ling\} and Ng, \{Khuen Yen\} and Chye, \{Soi Moi\} and Ling, \{Anna Pick Kiong\} and Ooi, \{Yin Yin\} and Koh, \{Rhun Yian\}",

note = "Funding Information: The project was supported by Ministry of Higher Education, Malaysia, grant number FRGS/1/2019/SKK08/MUSM/02/2. Publisher Copyright: {\textcopyright} 2023 Malaysian Society for Biochemistry and Molecular Biology. All rights reserved.",

year = "2023",

month = apr,

language = "English",

volume = "26",

pages = "77--82",

journal = "Malaysian Journal of Biochemistry \& Molecular Biology",

issn = "1511-2616",

publisher = "Malaysian Society for Biochemistry and Molecular Biology",

number = "1",

}

TY - JOUR

T1 - THE ROLES OF ANTIFIBROTIC THERAPIES IN POST-SARS-CoV-2 INFECTION

AU - Azni, Nur Azizah Nadhirah Binti

AU - Leong, Yong Qi

AU - Lim, Chooi Ling

AU - Ng, Khuen Yen

AU - Chye, Soi Moi

AU - Ling, Anna Pick Kiong

AU - Ooi, Yin Yin

AU - Koh, Rhun Yian

N1 - Funding Information: The project was supported by Ministry of Higher Education, Malaysia, grant number FRGS/1/2019/SKK08/MUSM/02/2. Publisher Copyright: © 2023 Malaysian Society for Biochemistry and Molecular Biology. All rights reserved.

PY - 2023/4

Y1 - 2023/4

N2 - Coronavirus Disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), has affected over hundred million people worldwide. Other than acute symptoms after infection, the patients are also suffering with long-term health complications associated with COVID-19 called long COVID or post-COVID conditions by which pulmonary fibrosis (PF) was observed in one-third of the patients. Since post-COVID-19-associated PF (PCPF) shares similar symptoms with idiopathic pulmonary fibrosis (IPF), the ongoing studies focuses on the potential use of therapeutic approaches for IPF in PCPF patients. Hence, this study summarises the potential roles of these therapies to treat the PCPF include antifibrotic drugs, mesenchymal stem cell (MSC) therapy and inhaled curcumin nanoformulations by assessing their efficacies for the PCPF treatment.

AB - Coronavirus Disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), has affected over hundred million people worldwide. Other than acute symptoms after infection, the patients are also suffering with long-term health complications associated with COVID-19 called long COVID or post-COVID conditions by which pulmonary fibrosis (PF) was observed in one-third of the patients. Since post-COVID-19-associated PF (PCPF) shares similar symptoms with idiopathic pulmonary fibrosis (IPF), the ongoing studies focuses on the potential use of therapeutic approaches for IPF in PCPF patients. Hence, this study summarises the potential roles of these therapies to treat the PCPF include antifibrotic drugs, mesenchymal stem cell (MSC) therapy and inhaled curcumin nanoformulations by assessing their efficacies for the PCPF treatment.

KW - Antifibrotic therapies

KW - Coronavirus Disease 19 (COVID-19)

KW - Pulmonary fibrosis

KW - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS)

UR - https://www.scopus.com/pages/publications/85175242184

M3 - Review Article

AN - SCOPUS:85175242184

SN - 1511-2616

VL - 26

SP - 77

EP - 82

JO - Malaysian Journal of Biochemistry & Molecular Biology

JF - Malaysian Journal of Biochemistry & Molecular Biology

IS - 1

ER -

THE ROLES OF ANTIFIBROTIC THERAPIES IN POST-SARS-CoV-2 INFECTION

Abstract

Keywords

Access to Document

Other files and links

Cite this